China Single Cell Analysis Market Size & Outlook, 2026-2033
The single cell analysis market in China is expected to reach a projected revenue of US$ 1,057.1 million by 2033. A compound annual growth rate of 23.57% is expected of China single cell analysis market from 2026 to 2033.
In terms of revenue, China accounted for 3.7% of the global single cell analysis market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China single cell analysis market is projected to lead the regional market in terms of revenue in 2033.
Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 870.5 million by 2033.
According to Novo tech in September 2023, China emerged as a hub for cell and gene therapy, securing the second position globally in patent applications and registered clinical trials, following the U.S. As per China CDC Weekly, in 2022, there was an increase of 15.85%, 68.62%, and −18.04% in cancer incidence, prevalence, and mortality compared to 244.75, 973.80, and 140.66 per 100,000 total population, respectively, in 2019.
Thus, market players are focusing on cancer immunotherapy-based products in China. Some of the major companies in the market are Innovative Cellular Therapeutics, Cellular Biomedicine Group, CARs gen Therapeutics, Person Gen Biomedicine, and Hebei Senlang Biotechnology.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Single Cell Analysis Market Outlook will help companies and investors design strategic landscapes.
Consumables was the largest segment with a revenue share of 64.62% in 2025.
Horizon Databook has segmented the China single cell analysis market based on instruments, consumables covering the revenue growth of each sub-segment from 2021 to 2033.
According to Novo tech in September 2023, China emerged as a hub for cell and gene therapy, securing the second position globally in patent applications and registered clinical trials, following the U.S. As per China CDC Weekly, in 2022, there was an increase of 15.85%, 68.62%, and −18.04% in cancer incidence, prevalence, and mortality compared to 244.75, 973.80, and 140.66 per 100,000 total population, respectively, in 2019.
Thus, market players are focusing on cancer immunotherapy-based products in China. Some of the major companies in the market are Innovative Cellular Therapeutics, Cellular Biomedicine Group, CARs gen Therapeutics, Person Gen Biomedicine, and Hebei Senlang Biotechnology.
China Single Cell Analysis Market Product Outlook (Revenue, USD Million , 2021-2033)
Consumables
Instruments
China Single Cell Analysis Market Application Outlook (Revenue, USD Million , 2021-2033)
Cancer
Immunology
Neurology
Stem Cell
Non invasive prenatal diagnosis
In vitro Fertilisation
Other Application
China Single Cell Analysis Market Workflow Outlook (Revenue, USD Million , 2021-2033)
Single Cell Isolation & Library Preparation
Downstream Analysis
Data Analysis
China Single Cell Analysis Market End Use Outlook (Revenue, USD Million , 2021-2033)
Academic & Research Laboratories
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Laboratories
Other End Use
Reasons to subscribe to Single Cell Analysis Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Single Cell Analysis Market Outlook databook
Our clientele includes a mix of Single Cell Analysis Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Single Cell Analysis Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Single Cell Analysis Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
China Single Cell Analysis Market, 2021-2033 (US$M)